Astrana Health (ASTH) Gets Upgraded by Barclays

Astrana Health, Inc. (NASDAQ:ASTH) is one of the best small cap stocks to buy for the long term. Astrana Health, Inc. (NASDAQ:ASTH) got upgraded to Overweight from Equal Weight by Barclays on May 26, with the firm lifting the price target on the stock to $50 from $37. It told investors in a research note that it believes the outlook for value-based care has “materially improved in recent weeks, driven by encouraging signs” of stabilizing cost trends and a more favorable 2027 Medicare Advantage rate outcome. It added that the company has room for multiple expansions as it executes on its integration of Prospect and accelerates full-risk membership growth.

10 Unhealthiest Countries In Asia

For additional reference, in its financial results for fiscal Q1 2026 released on May 7, Astrana Health, Inc. (NASDAQ:ASTH) reported total revenue of $965.1 million, reflecting a 56% year over year growth. It also reported adjusted EBITDA of $66.3 million, up 82% year over year, and free cash flow of $64.1 million, up 372% year over year.

Astrana Health, Inc. (NASDAQ:ASTH) is a physician-centric, technology-powered, risk-bearing healthcare management company that operates as an integrated healthcare delivery platform. It provides services including Multi-Specialty Care, Primary Care, Radiology, Immediate Care, and Laboratory.

While we acknowledge the risk and potential of ASTH as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ASTH and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1